Skip to main content

Table 1 Key In- and Exclusion Criteria for PATRON07 and BUILT_01

From: Study Protocol: A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function. PATRON-Study

Inclusion Criteria

Exclusion Criteria

Patients undergoing primary liver transplantation.

Patients with pre-transplant renal replacement therapy > 14 days.

Patients older than 18 years.

Patients with platelets < 50.000/nl.

eGFR < 50 ml/min at the time point of transplantation

Patients with triglycerides > 350 mg/dl and cholesterol > 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition.

Serum creatinine levels > 1.5 mg/dL at the time-point of transplantation

Multiple organ graft recipients.

Patients with eGFR < 50 ml/min at the time point of transplantation or Serum creatinine levels > 1.5 mg/dL at the time-point of transplantation

Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with Sirolimus.

 

Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.

 

Patients under guardianship (e.g. individuals who are not able to freely give their informed consent).